How should a 7 mm low‑attenuation focus in the pancreatic body, possibly representing a partial‑volume artifact versus a cyst, be evaluated and managed?

Management of a 7 mm Low-Attenuation Pancreatic Body Focus

For a 7 mm low-attenuation pancreatic focus that may represent a partial-volume artifact versus a true cyst, obtain dedicated MRI with MRCP (with and without IV contrast) for definitive characterization, followed by a single follow-up imaging study at 2 years if confirmed as a small cyst without worrisome features. 1

Initial Diagnostic Approach

Obtain MRI abdomen with and without IV contrast plus MRCP as the definitive characterization study. 1 This modality is superior to CT for:

• Distinguishing true cystic lesions from partial-volume artifacts
• Detecting worrisome features including mural nodules, thick septations, or main pancreatic duct communication 1
• Establishing a baseline for future surveillance without radiation exposure 2
• Providing superior soft tissue contrast and pancreatic ductal anatomy delineation 1

The ACR Appropriateness Criteria specifically recommend MRI with MRCP as the initial evaluation for incidentally detected pancreatic cysts, particularly those <2.5 cm. 1

Risk Stratification Based on MRI Findings

If Confirmed as a Simple Cyst <5 mm:

• One follow-up MRI or CT at 2 years is sufficient 1
• If stable at 2 years, discontinue surveillance 1
• The annual malignant transformation risk is only 0.24% per year for all pancreatic cysts 1, 2

If Confirmed as a Cyst 5-10 mm Without Worrisome Features:

• Follow-up imaging at 1 year, then every 2 years for 5 years 2
• After 5 years of stability, consider stopping surveillance 2

If Worrisome Features Are Present:

Look specifically for these high-risk features on MRI:

• Main pancreatic duct dilation >7 mm (57-92% malignancy risk) 1
• Enhancing mural nodules or solid components (8-fold increased malignancy risk) 1, 2
• Thick septations 1
• Cyst size ≥3 cm (3-fold increased malignancy risk) 2

If any worrisome features are identified, proceed to EUS-FNA for tissue diagnosis 1

Key Clinical Pitfalls to Avoid

Do not use CT as the initial characterization study for small pancreatic lesions. 1 While CT can detect cysts, it:

• Exposes patients to unnecessary radiation for a likely benign finding 2
• Is inferior to MRI for detecting subtle worrisome features 1
• Cannot reliably distinguish partial-volume artifacts from true small cysts 3

Do not initiate aggressive surveillance protocols for lesions <5 mm. 1 The evidence shows that cysts <5 mm have extremely low malignant potential and require only one confirmatory follow-up study. 1

Ensure accurate size measurement. Recent evidence demonstrates that single maximum diameter measurements overestimate cyst volume compared to average diameter measurements (mean difference of 2.8 mm in one study), potentially leading to overtreatment. 4, 5 However, current guidelines still use maximum diameter for risk stratification. [1-2]

Attenuation Characteristics

If the lesion is visible on CT, attenuation values can provide additional diagnostic information:

• Pseudocysts typically measure >14.5 HU 3
• Mucinous cysts (MCN/IPMN) typically measure <14.5 HU 3
• This 14.5 HU threshold has 73.5% accuracy for differentiation 3

However, this should not replace MRI for definitive characterization of small lesions. 1

Surveillance Modality Selection

Either MRI or CT can be used for follow-up surveillance once the cyst is characterized. 1 There is no evidence that MRI is superior to CT for detecting interval changes in established cysts. 1 However, MRI is preferred for:

• Younger patients requiring long-term surveillance (radiation avoidance) 2
• Initial characterization studies 1
• Detection of enhancing mural nodules if contrast is used 1

If using CT for follow-up, perform dual-phase pancreatic protocol CT (late arterial and portal venous phases). 1